1. Home
  2. ENLV vs ITRM Comparison

ENLV vs ITRM Comparison

Compare ENLV & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$0.83

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.34

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENLV
ITRM
Founded
2005
2015
Country
Israel
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
24.3M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
ENLV
ITRM
Price
$0.83
$0.34
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$9.00
AVG Volume (30 Days)
11.7M
670.5K
Earning Date
11-28-2025
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$390,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$325.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$0.35
52 Week High
$2.10
$2.10

Technical Indicators

Market Signals
Indicator
ENLV
ITRM
Relative Strength Index (RSI) 36.38 29.55
Support Level $0.80 $0.44
Resistance Level $0.88 $0.49
Average True Range (ATR) 0.09 0.04
MACD -0.02 -0.00
Stochastic Oscillator 6.69 8.22

Price Performance

Historical Comparison
ENLV
ITRM

About ENLV Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: